Cargando…
Evaluation of the TEG(® )platelet mapping™ assay in blood donors
BACKGROUND: Monitoring of antiplatelet therapy in patients at cardiovascular risk is difficult because existing platelet function tests are too sophisticated for clinical routine. The whole blood TEG(® )Platelet Mapping™ assay measures clot strength as maximal amplitude (MA) and enables for quantifi...
Autores principales: | Bochsen, Louise, Wiinberg, Bo, Kjelgaard-Hansen, Mads, Steinbrüchel, Daniel A, Johansson, Pär I |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1804261/ https://www.ncbi.nlm.nih.gov/pubmed/17311677 http://dx.doi.org/10.1186/1477-9560-5-3 |
Ejemplares similares
-
TEG® and RapidTEG® are unreliable for detecting warfarin-coagulopathy: a prospective cohort study
por: Dunham, C Michael, et al.
Publicado: (2014) -
Exercise induced hypercoagulability, increased von Willebrand factor and decreased thyroid hormone concentrations in sled dogs
por: Krogh, Anne KH, et al.
Publicado: (2014) -
TEG Platelet Mapping and Impedance Aggregometry to Predict Platelet Transfusion During Cardiopulmonary Bypass in Pediatric Patients
por: Barker, Erin E., et al.
Publicado: (2019) -
TEG(®), Microclot and Platelet Mapping for Guiding Early Management of Severe COVID-19 Coagulopathy
por: Laubscher, Gert Jacobus, et al.
Publicado: (2021) -
Thrombelastographic haemostatic status and antiplatelet therapy after coronary artery bypass surgery (TEG-CABG trial): assessing and monitoring the antithrombotic effect of clopidogrel and aspirin versus aspirin alone in hypercoagulable patients: study protocol for a randomized controlled trial
por: Rafiq, Sulman, et al.
Publicado: (2012)